Add-on Acquisition • Life Science

Bristol-Myers Squibb Acquires Celgene

On January 3, 2019, Bristol-Myers Squibb acquired life science company Celgene for 74.0B USD

Acquisition Context

This is Bristol-Myers Squibb’s 17th transaction in the Life Science sector.
This is Bristol-Myers Squibb’s largest (disclosed) transaction.
This is Bristol-Myers Squibb’s 14th transaction in the United States.
This is Bristol-Myers Squibb’s 2nd transaction in New Jersey.

Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	January 3, 2019
Target	Celgene
Sector	Life Science
Buyer(s)	Bristol-Myers Squibb
Deal Type	Add-on Acquisition
Deal Value	74.0B USD
Advisor(s)	J.P. Morgan Securities Citi (Financial) Wachtell, Lipton, Rosen & Katz (Legal)

Target Company

Celgene

Summit, New Jersey, United States

Celgene Corp. is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. Celgene Corp. was established in 1980 and is headquartered in Summit, New Jersey.

Explore More Deals

Browse All 215,156 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

Bristol-Myers Squibb

Princeton, New Jersey, United States

Category	Company
Founded	1887
Sector	Life Science
Employees	34,100
Revenue	48.3B USD (2024)

DESCRIPTION

Bristol-Myers Squibb is a life science company engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Bristol-Myers Squibb was incorporated in 1887 and is based in Princeton, New Jersey.

Deal Context for Buyer	#
Overall	17 of 25
Sector: Life Science	17 of 25
Type: Add-on Acquisition	16 of 23
State: New Jersey	2 of 2
Country: United States	14 of 22
Year: 2019	1 of 1
Size (of disclosed)	1 of 21

PREVIOUS DEAL

DATE	TARGET	DEAL TYPE	VALUE
2018-10-08	Upsa France Upsa is a provider of an over-the-counter drugs business. Upsa is based in France.	Sell	-

DATE

TARGET

DEAL TYPE

VALUE

2018-10-08

Upsa

France

Upsa is a provider of an over-the-counter drugs business. Upsa is based in France.

Sell

FOLLOWING DEAL

DATE	TARGET	DEAL TYPE	VALUE
2019-06-19	Bristol-Myers Squibb Co. - Anagni Manufacturing Facility Anagni, Italy Bristol-Myers Squibb Co. - Anagni Manufacturing Facility is a provider of oral solid, biologics, and sterile product manufacturing and packaging facility.	Sell	-

DATE

TARGET

DEAL TYPE

VALUE

2019-06-19

Bristol-Myers Squibb Co. - Anagni Manufacturing Facility

Anagni, Italy

Bristol-Myers Squibb Co. - Anagni Manufacturing Facility is a provider of oral solid, biologics, and sterile product manufacturing and packaging facility.

Sell

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - New Jersey M&A - United States M&A - 2019 M&A